Nanobiotechnology is a branch of nanotechnology with biological and biochemical applications. Professor Iyer’s research explores the design and development of multimodal nanoparticles which seek to expand upon the benefits of the first- generation, clinically tested nanoparticles by adding functionalities intended to improve delivery, therapeutic efficacy, and ultimately patient outcome. This will help make informed decisions about timing, dosage, drug choice, and treatment strategies. Such personalized medicine can lead to improved efficacy, lower off-target toxicity, and an overall increase in quality of life and patient outcome.

Professor Iyer specialises in nanobiotechnology (or bionanotechnology) – an interdisciplinary field that draws on materials & polymer chemistry, biophysics, biology and nanotechnology. In particular, he is focusing his research efforts on the design and development of multifunctional polymeric nanoparticles, capable of delivering imaging and therapeutic agents to specific cells or organs, thereby enabling detection and treatment of disease in a single procedure.

Professor Iyer’s nanoforumation technology uses a novel polymeric composition that enables encapsulation of multiple components or “payload” , stable delivery of the payload to the target cells and simultaneous imaging/tracking.

“This formulation has shown promising applications achieving high transfer efficiency and targeted drug delivery for neurotrauma, in tissue engineering, treatment of cancer cardiovascular diseases and more recently in treating placental related disorders during pregnancy,” he said.

“The successful implementation of this technology is dependent on our detailed understanding of the nanoparticle-cell interactions”, he continues. “We will address this very important issue by evaluating a range of surface functionalised nanoparticles in highly significant models of medical emergencies. This project will enable development of advanced therapeutic interventions for cancer, central nervous system injuries, cardiovascular diseases and pregnancy related disorders.”

Professor Iyer has helped set up a new spin-out company, Eridan Technology Pty Ltd, to commercialise nanoparticle technology for drug delivery applications. His research team believes the technology will significantly improve single-dose drug delivery targeting specific sites in the body.

Collaborator/s

  • Standford University
  • Cambridge University
  • Virginia Tech
  • Clemson University
  • Cardiff University
  • University of San Diego
  • Centre for Cellular and Molecular Biology (CCMB)